Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CXCR2 | P25025 | 3/20 | 0.43 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.38 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.33 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 1/20 | 0.31 |
| ▸ | MDM4 | O15151 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11148654 | 0.79 | CXCR2 (0.41) | NPSR1ALDH1A1CXCR2CXCR1CA2 | |
| SCHEMBL18630360 | 0.79 | DPP4 (0.41) | NPSR1ALDH1A1CXCR2CXCR1CA2 | |
| SCHEMBL8624140 | 0.79 | CXCR2 (0.41) | NPSR1CXCR2CXCR1CA2CXCL8 | |
| SCHEMBL26452085 | 0.79 | CXCR2 (0.41) | NPSR1CXCR2CXCR1CA2CXCL8 | |
| SCHEMBL21966974 | 0.79 | CXCR2 (0.41) | NPSR1CXCR2CXCR1CA2CXCL8 | |
| SCHEMBL28420215 | 0.78 | ALDH1A1 (0.44) | NPSR1ALDH1A1CA2CA1CA9 | |
| SCHEMBL23869332 | 0.76 | ALDH1A1 (0.42) | NPSR1ALDH1A1CA2CA1CA9 | |
| SCHEMBL84561 | 0.76 | ALDH1A1 (0.42) | NPSR1ALDH1A1CA2CA1CA9 | |
| SCHEMBL24915652 | 0.76 | ALDH1A1 (0.42) | NPSR1ALDH1A1CA2CA1CA9 | |
| SCHEMBL10254652 | 0.76 | ALDH1A1 (0.47) | NPSR1ALDH1A1CA2CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 278 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720034-A1 | NOVEL COMPOUNDS TO TREAT VIRAL INFECTIONS | Zydus Lifesciences Limited (IN) | 2026-04-08 | — | — | EP | claimed |
| WO-2024252254-A1 | NOVEL COMPOUNDS TO TREAT VIRAL INFECTIONS | ZYDUS LIFESCIENCES LIMITED (IN) | 2024-12-12 | — | — | WO | claimed |
| EP-4720034-A1 | NOVEL COMPOUNDS TO TREAT VIRAL INFECTIONS | Zydus Lifesciences Limited (IN) | 2026-04-08 | — | — | EP | disclosed |
| US-20260055062-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC | 2026-02-26 | — | — | US | disclosed |
| WO-2024252254-A1 | NOVEL COMPOUNDS TO TREAT VIRAL INFECTIONS | ZYDUS LIFESCIENCES LIMITED (IN) | 2024-12-12 | — | — | WO | disclosed |
| US-20240391904-A1 | DIHYDROPYRIMIDINE BASED COMPOUND, PREPARATION METHOD THEREFOR AND USE OF THEREOF | CHENGDU SHIBEIKANG BIOMEDICAL TECHNOLOGY CO., LTD. (CN) | 2024-11-28 | — | — | US | disclosed |
| WO-2024217513-A1 | β-CATENIN/BCL9 PROTEIN-PROTEIN INTERACTION INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 复旦大学 | 2024-10-24 | — | — | WO | disclosed |
| US-20240287029-A1 | SULFONAMIDES, METHOD FOR PREPARATION THEREOF, AND USE THEREOF | CHENGDU SHIBEIKANG BIOMEDICAL TECHNOLOGY CO., LTD. (CN) | 2024-08-29 | — | — | US | disclosed |
| EP-4410786-A1 | SULFONAMIDE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Chengdu Shibeikang Biomedical Technology Co., Ltd. (CN) | 2024-08-07 | — | — | EP | disclosed |
| EP-4410785-A1 | DIHYDROPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Chengdu Shibeikang Biomedical Technology Co., Ltd. (CN) | 2024-08-07 | — | — | EP | disclosed |
| US-12037324-B2 | Biarylmethyl heterocycles | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| US-20070259929-A1 | Therapeutic Compounds | ALLERGAN, INC. | 2007-11-08 | — | — | US | disclosed |
| US-20070259929-A1 | Therapeutic Compounds | ALLERGAN, INC. | 2007-11-08 | — | — | US | disclosed |
| US-20070225285-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070219206-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-09-20 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155737-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155737-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070105832-A1 | Substituted azetidinones | Cadrenal Therapeutics, Inc. | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105832-A1 | Substituted azetidinones | F2R, CPA3, CFD | NPSR1 1095/4885ALDH1A1 2503/4885CXCR2 1078/4885 |
| US-20070155737-A1 | Heterobicyclic metalloprotease inhibitors | ADAMTS4, ADAMTS1, ADAMTS5 | NPSR1 489/4885ALDH1A1 3954/4885CXCR2 2364/4885 |
| US-20070225285-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | ALOX5, ALOX15B, ALOX15 | NPSR1 4409/4885ALDH1A1 1358/4885CXCR2 1510/4885 |
| US-20240287029-A1 | SULFONAMIDES, METHOD FOR PREPARATION THEREOF, AND USE THEREOF | P2RX3, P2RX5, P2RX2 | NPSR1 89/4885ALDH1A1 2252/4885CXCR2 90/4885 |
| US-20070259929-A1 | Therapeutic Compounds | PIGO, CYC1, COXFA4L2 | NPSR1 2050/4885ALDH1A1 747/4885CXCR2 1076/4885 |
| US-20070219206-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | ALOX5, ALOX15B, ALOX15 | NPSR1 4409/4885ALDH1A1 1358/4885CXCR2 1510/4885 |
| US-20240391904-A1 | DIHYDROPYRIMIDINE BASED COMPOUND, PREPARATION METHOD THEREFOR AND USE OF THEREOF | P2RX3, P2RX6, P2RX7 | NPSR1 306/4885ALDH1A1 685/4885CXCR2 404/4885 |
| US-12037324-B2 | Biarylmethyl heterocycles | ARRB1, ADRB2, ADRB1 | NPSR1 98/4885ALDH1A1 919/4885CXCR2 365/4885 |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | NPSR1 2352/4885ALDH1A1 1806/4885CXCR2 803/4885 |
| US-20260055062-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | SLC16A1, SLC16A3, SLC16A7 | NPSR1 2796/4885ALDH1A1 559/4885CXCR2 443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.